Genmab Advances Share Buy-back Program in June 2025

Genmab ( (GMAB) ) has provided an announcement.

On June 10, 2025, Genmab A/S announced the continuation of its share buy-back program, initiated on March 25, 2025, to repurchase up to 2.2 million shares. The program, aimed at reducing capital and fulfilling commitments under the Restricted Stock Unit program, saw transactions executed from June 2 to June 6, 2025, with a total of 400 shares bought back during this period. Following these transactions, Genmab holds 2,532,038 shares as treasury shares, representing 3.95% of the total share capital and voting rights.

The most recent analyst rating on (GMAB) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.

Spark’s Take on GMAB Stock

According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.

Genmab’s overall stock score is driven primarily by its strong financial performance, with a robust balance sheet and effective cash flow management. The technical analysis also supports a positive outlook, although the stock may be nearing overbought levels. Valuation metrics are favorable, though the lack of a dividend yield is a minor drawback.

To see Spark’s full report on GMAB stock, click here.

More about Genmab

Genmab is an international biotechnology company headquartered in Copenhagen, Denmark. It focuses on developing innovative and differentiated antibody therapeutics, with a proprietary pipeline that includes bispecific T-cell engagers, antibody-drug conjugates, and next-generation immune checkpoint modulators. The company aims to transform the lives of people with cancer and other serious diseases by 2030.

Average Trading Volume: 1,473,745

Technical Sentiment Signal: Sell

Current Market Cap: $13.57B

Find detailed analytics on GMAB stock on TipRanks’ Stock Analysis page.